| SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor M Hoffmann, H Kleine-Weber, S Schroeder, N Krüger, T Herrler, ... cell 181 (2), 271-280. e8, 2020 | 22606 | 2020 |
| Virological assessment of hospitalized patients with COVID-2019 R Wölfel, VM Corman, W Guggemos, M Seilmaier, S Zange, MA Müller, ... Nature 581 (7809), 465-469, 2020 | 6413 | 2020 |
| Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC VS Raj, H Mou, SL Smits, DHW Dekkers, MA Müller, R Dijkman, D Muth, ... Nature 495 (7440), 251-254, 2013 | 2455 | 2013 |
| Severe acute respiratory syndrome coronavirus 2− specific antibody responses in coronavirus disease patients NMA Okba, MA Müller, W Li, C Wang, CH GeurtsvanKessel, VM Corman, ... Emerging infectious diseases 26 (7), 1478, 2020 | 1676 | 2020 |
| SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 J Braun, L Loyal, M Frentsch, D Wendisch, P Georg, F Kurth, ... Nature 587 (7833), 270-274, 2020 | 1317 | 2020 |
| Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response I Glowacka, S Bertram, MA Müller, P Allen, E Soilleux, S Pfefferle, I Steffen, ... Journal of virology 85 (9), 4122-4134, 2011 | 1283 | 2011 |
| Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study CBEM Reusken, BL Haagmans, MA Müller, C Gutierrez, GJ Godeke, ... The Lancet infectious diseases 13 (10), 859-866, 2013 | 937 | 2013 |
| The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells M Hoffmann, H Kleine-Weber, N Krüger, M Müller, C Drosten, ... BioRxiv, 2020.01. 31.929042, 2020 | 892 | 2020 |
| Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction VM Corman, I Eckerle, T Bleicker, A Zaki, O Landt, M Eschbach-Bludau, ... Eurosurveillance 17 (39), 2012 | 751 | 2012 |
| Bats host major mammalian paramyxoviruses JF Drexler, VM Corman, MA Müller, GD Maganga, P Vallo, T Binger, ... Nature communications 3 (1), 796, 2012 | 742 | 2012 |
| Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19 M Hoffmann, S Schroeder, H Kleine-Weber, MA Müller, C Drosten, ... Antimicrobial agents and chemotherapy 64 (6), 10.1128/aac. 00754-20, 2020 | 524 | 2020 |
| Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection C Drosten, M Seilmaier, VM Corman, W Hartmann, G Scheible, S Sack, ... The Lancet infectious diseases 13 (9), 745-751, 2013 | 519 | 2013 |
| Serological assays for emerging coronaviruses: challenges and pitfalls B Meyer, C Drosten, MA Müller Virus research 194, 175-183, 2014 | 509 | 2014 |
| Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA … JF Drexler, F Gloza-Rausch, J Glende, VM Corman, D Muth, M Goettsche, ... Journal of virology 84 (21), 11336-11349, 2010 | 486 | 2010 |
| Transmission of MERS-coronavirus in household contacts C Drosten, B Meyer, MA Müller, VM Corman, M Al-Masri, R Hossain, ... New England Journal of Medicine 371 (9), 828-835, 2014 | 485 | 2014 |
| Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 M Hoffmann, K Mösbauer, H Hofmann-Winkler, A Kaul, H Kleine-Weber, ... Nature 585 (7826), 588-590, 2020 | 478 | 2020 |
| Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection VM Corman, AM Albarrak, AS Omrani, MM Albarrak, ME Farah, M Almasri, ... Clinical Infectious Diseases 62 (4), 477-483, 2016 | 478 | 2016 |
| Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections VM Corman, MA Müller, U Costabel, J Timm, T Binger, B Meyer, P Kreher, ... Eurosurveillance 17 (49), 20334, 2012 | 478 | 2012 |
| Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform T Thi Nhu Thao, F Labroussaa, N Ebert, P V’kovski, H Stalder, J Portmann, ... Nature 582 (7813), 561-565, 2020 | 470 | 2020 |
| The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors S Pfefferle, J Schöpf, M Kögl, CC Friedel, MA Müller, J Carbajo-Lozoya, ... PLoS pathogens 7 (10), e1002331, 2011 | 467 | 2011 |
Christian DrostenDirector, Institute of Virology, Charite Universitätsmedizin BerlinOverená e-mailová adresa na: charite.de
